‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
MarketWatch· Jaimy Lee· Oct 13, 2026 · 3:37 PM
The Federal Trade Commission and seven states say Shkreli should be held in contempt
This is a summary. Read the complete story at MarketWatch below.
Read full article at MarketWatchRelated Stories
marketsabout 3 hours ago
My wife says we can’t afford to retire, yet she wants to take an $8,000 trip to Italy. We have $4 million. Do I keep working?
“I worry about healthcare, long-term care, inflation, a long bear market and living to 95.”
MarketWatch
marketsabout 3 hours ago
Who should pay for a birthday dinner? I always treat my guests.
“I feel like I just end up paying for other people’s birthday dinners a lot, as well as my own, which is an imbalance.”
MarketWatch
marketsabout 3 hours ago
Hedge-fund legend Paul Tudor Jones says the stock market faces a really challenging 2027. Here’s why.
U.S. stocks could face a serious test in 2027 as a tsunami of new equity issuance threatens to upend the artificial-intelligence-driven bull market, according to hedge-fund billionaire Paul Tudor Jones.
MarketWatch